From: Development of therapeutic antibodies for the treatment of diseases
No. | Drug | Indication (1st US FDA Approval Year) | Company | 2018 Revenue (USD) |
---|---|---|---|---|
1 | Adalimumab (Humira) | Rheumatoid arthritis (2002) Psoriatic arthritis (2005) Ankylosing spondylitis (2006) Juvenile Idiopathic Arthitis (2008) Psoriasis (2008) Crohn’s disease (2010) Ulcerative colitis (2012) Hidradenitis suppurativa (2015) Uveitis (2018) | AbbVie | $19.9 bn |
2 | Nivolumab (Opdivo) | Melanoma (2015) Non-small cell lung cancer (2015) Renal cell carcinoma (2015) Head and neck squamous cell (2016) | Bristol-Myers Squibb | $7.6 bn |
3 | Pembrolizumab (Keytruda) | Melanoma (2014) Head and neck cancer (2016) Non-small cell lung caccer (2015) Lymphoma (2018) Cervical cancer (2018) Microsatellite instability-high cancer (2018) | Merck & Co | $7.2 bn |
4 | Trastuzumab (Herceptin) | Breast cancer (1998) Gastric cancer (2010) | Roche | $7.0 bn |
5 | Bevacizumab (Avastin) | Colorectal cancer (2004) Non-small cell lung caccer (2006) Breast ERB2 negative cancer (2008) Renal cell carcinoma (2009) Glioblastoma (2011) | Roche | $6.8 bn |
6 | Rituximab, (Rituxan) | Non-Hodgkin’s lymphoma (1997) Chronic lymphocytic leukemia (2010) Rheumatoid arthritis (2006) Pemphigus vulgaris (2018) | Roche | $6.8 bn |
7 | Infliximab (Remicade) | Crohn’s Disease (1998) Rheumatoid arthritis (1999) Ankylosing spondylitis (2004) Ulcerative colitis (2005) Psoriatic arthritis (2005) Psoriasis (2006) | Johnson & Johnson | $5.9 bn |
8 | Ustekinumab (Stelara) | Psoriasis (2009) Psoriatic arthritis (2013) Crohn’s Disease (2016) | Johnson & Johnson | $5.2 bn |
9 | Eculizumab (Soliris) | Paroxysmal nocturnal hemoglobinuria (2007) Atypical hemolytic uremic syndrome (2011) Generalized myasthenia gravis (2017) Neuromyelitis optica spectrum disorder (2019) | Alexion | $3.6 bn |
10 | Omalizumab (Xolair) | Asthma (2003) Chronic idiopathic urticaria (2014) | Roche | $3.0 bn |